SunTrust Out On La Jolla Pharma's Receipt Of NTAP Coverage for GIAPREZA; Firm Calls It a 'Potential Game Changer,' Says It Could Dramatically INcrease the Uptake of GIAPREZA By Hospital Systems Since the CMS Will Effectively Cover 50% of the Drug's Cost
Benzinga Newsdesk